Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153434 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
A Phase 2 study of Prader-Willi Syndrome, sponsored by Aardvark Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT05153434 is a Phase 2 study of Prader-Willi Syndrome that has completed, run by Aardvark Therapeutics. The registered enrollment target is 19 participants, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05153434, a Phase 2 study of Prader-Willi Syndrome, has completed, sponsored by Aardvark Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
Conditions Studied
Interventions
- DRUG ARD-101
Study Locations (2)
California
- Stanford University - Palo Alto
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2024-09-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05153434
The ClinicalTrials.gov registry entry for NCT05153434 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (73% lower). The listed sponsor is Aardvark Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 1 intervention - of which ARD-101 is the first listed.
NCT05153434 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05153434 about?
NCT05153434 is a clinical study titled "A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome". A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
What is the current status of trial NCT05153434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2022-05-27. Estimated completion is 2024-09-24.
What conditions does trial NCT05153434 study?
This clinical trial studies the following conditions: Prader-Willi Syndrome.
What interventions are being tested in trial NCT05153434?
The interventions under investigation include: ARD-101 (DRUG).
Who is sponsoring clinical trial NCT05153434?
This trial is sponsored by Aardvark Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05153434 being conducted?
This trial has 2 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prader-Willi Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
COMPLETED · Phase 2
-
Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome
COMPLETED · Phase 2
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.